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The use of a positive-displacement needleless intravenous access device was associated with lower mi-
crobial contamination rates compared with a neutral-displacement device when used on central venous
catheters in hemato-oncology patients. In addition, rates of central line–associated bloodstream infec-
tion did not differ when either device was used.
© 2016 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier
Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
There have been conﬂicting opinions regarding the effect of
needleless intravenous (IV) access devices on the incidence of blood-
stream infection (BSI).1 The Society for Healthcare Epidemiology of
America and the Infectious Diseases Society of America previ-
ously advised that “positive-pressure needleless connectors with
mechanical valves should not be used before a thorough
assessment.”2 The Food and Drug Administration consequently re-
quested that manufacturers of positive-displacement devices
demonstrate that they are not associated with an increased risk of
central line–associated bloodstream infection (CLABSI).3 The Society
for Healthcare Epidemiology of America and Infectious Diseases
Society of America practice recommendations now state that “the
optimal design for preventing infections is unresolved.”4
The present study investigated external and internal microbial
contamination of a positive- and a neutral-displacement needleless
IV access device.
METHODS
Approval for this study was granted by the East Midlands Re-
search Ethics Committee (13/EM/0247). Consent was obtained for
needleless IV access device sampling.
An opaque neutral-displacement device (MicroClave; Fannin,
Wellingborough, UK) was routinely used on patients’ central venous
catheter (CVC) on the hemato-oncology ward at the University Hos-
pitals NHS Foundation Trust. Nurses were trained to disinfect the
septum of each device prior to and after each access for 30 seconds
with a wipe containing 2% wt/vol chlorhexidine and 70% vol/vol iso-
propanol, followed by drying for 30 seconds. The microbial
contamination rate of this device was investigated for 3 months.
Health care workers were then trained to use a transparent positive-
displacement device (MaxPlus Clear; CareFusion, San Diego, CA). This
device was implemented for a 1-month washout period, and mi-
crobial contamination was subsequently investigated for 6 months.
The neutral-displacement device was then reimplemented, and after
1 month microbial contamination was studied for 3 months. Hos-
pital IV guidelines were followed, and needleless devices were
* Address correspondence to T.S.J. Elliott, DSc, University Hospitals Birmingham
National Health Service Foundation Trust, The Queen Elizabeth Hospital, Edgbaston,
Birmingham, B15 2TH, UK.
E-mail address: tom.elliott@uhb.nhs.uk (T.S.J. Elliott).
Previous Presentation: Presented in part at the 4th World Congress on Vascu-
lar Access, June 22-24, 2016, Lisbon, Portugal.
Funding/Support: CareFusion, Inc funded this research and provided positive-
displacement needleless intravenous access devices and training. They were not
involved in any other part of this study.
Conﬂicts of Interest: A.L.C. and T.S.J.E. have received honoraria from CareFusion,
Inc, for participation in advisory board meetings and symposia. T.J.K. and P.N. have
no conﬂicts to declare.
0196-6553/© 2016 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
http://dx.doi.org/10.1016/j.ajic.2016.06.027
American Journal of Infection Control 44 (2016) 1678-80
Contents lists available at ScienceDirect
American Journal of Infection Control
journal homepage: www.aj ic journal .org
American Journal of 
Infection Control
replaced every 7 days. Aseptically removed devices were placed into
separate sterile specimen bags and stored at 4°C until processed.
In a previous study, the internal contamination rate of a needleless
IV access device was 26.1%.5 This negative-displacement device has
been associated with a comparable level of microbial ingress with
the neutral-displacement device used in our hospital.5 A sample size
of 416 devices (208 in each arm) would therefore have 90% power
to detect a decrease of 50% in the positive-displacement group at
a 5% signiﬁcance level.
The septum of each device was imprinted onto the surface of a
D/E neutralizing agar plate (BD, Oxford, UK) 10 times. The septa were
then decontaminated with a 70% vol/vol isopropanol wipe (Uni-
versal Hospital Supplies, Enﬁeld, UK) placed in individual sterile
containers and sonicated at 50 Hz for 10 minutes. A 1 mL syringe
was then attached to each end of the device, and 1 μL of D/E broth
was ﬂushed back and forth 5 times. Then 250 μL of each solution
were inoculated onto 5% blood agar (bioMérieux, Basingstoke, UK)
in duplicate. Culture plates were incubated at 37°C for 48 hours in
air; colony forming units were enumerated and then identiﬁed by
Matrix-Assisted Laser Desorption/Ionization - Time Of Flight (MALDI-
TOF) (VITEK MS; bioMérieux).
The rate of CLABSI and nonmucosal barrier injury–related
laboratory-conﬁrmed BSI (MBI-LCBI) CLABSI was determined on the
hemato-oncology ward and was expressed per 1,000 patient days
(the number of CVC days was unavailable).6 Rates of CLABSI were
compared using the mid-P exact test.
RESULTS
There were 557 needleless IV access devices connected to 167
CVCs (86 in the neutral- and 81 in the positive-displacement group)
from 157 patients that were studied (2 CVCs were studied in 10 pa-
tients). Patient demographics and CVC information are outlined in
Table 1. There were no differences between the study groups, with
the exception that the positive-displacement devices were in place
longer.
There was no difference in the rates of CLABSI between the ﬁrst
neutral-, the positive-, and the second neutral-displacement device
periods (7.52, 6.62, and 6.30 per 1,000 patient days, respectively;
ﬁrst neutral-displacement device vs positive-displacement device:
P = .60; ﬁrst neutral-displacement device vs second neutral-
displacement device: P = .56; positive-displacement device vs second
neutral-displacement device: P = .85). There was also no differ-
ence in the rates of non–MBI-LCBI CLABSI between the 3 periods
(4.30, 3.42, and 2.00 per 1,000 patient days respectively; ﬁrst neutral-
displacement device vs positive-displacement device: P = .49; ﬁrst
neutral-displacement device vs second neutral-displacement device:
P = .11; positive-displacement device vs second neutral-displacement
device: P = .19).
The number of needleless IV access devices contaminated and
the number of colony forming units isolated are summarized in
Table 2. Fewer septa and internal ﬂuid pathways were contami-
nated in the positive- compared with the neutral-displacement
Table 1
Patient demographics and central venous catheters
Patient and CVC details
Neutral-displacement
needleless IV access device
Positive-displacement
needleless IV access device P value
No. of patients studied 84 78 NA
Median age, y (range) 59.5 (22-73) 57 (24-73) .33*
Female/male ratio 30/54 27/51 >.99†
Clinical diagnosis .35*
Anemia 0 (0) 2 (2.6)
Ewing sarcoma 0 (0) 1 (1.3)
Germ cell tumor 1 (1.2) 1 (1.3)
Leukemia 31 (36.9) 20 (25.6)
Lymphoma 22 (26.2) 26 (33.3)
Myelodysplasia 3 (3.6) 6 (7.7)
Myeloﬁbrosis 1 (1.2) 2 (2.6)
Myeloma 26 (31.0) 20 (25.6)
Stem cell transplant during study participation 69 (82.1) 64 (82.1) >.99†
Neutropenia during participation on study 78 (92.9) 75 (96.2) .50†
Median no. of CVCs studied per patient (range) 1 (1-2) 1 (1-2) .87*
Type of CVC .28*
Single-lumen Hickman line 2 (2.3) 0 (0)
Double-lumen Hickman line 50 (58.1) 51 (63.0)
Single-lumen PICC 8 (9.3) 3 (3.7)
Double-lumen PICC 26 (30.2) 25 (30.9)
Quad-lumen nontunneled CVC 0 (0) 1 (1.2)
Femoral vascath 0 (0) 1 (1.2)
Median no. of days CVCs in situ prior to each device being attached (range)‡ 12 (0-186) 13 (0-264) .06*
Median no. of devices studied per CVC (range) 2 (1-12) 3 (1-14) .50*
No. of days devices in situ <.001§
1 2 (0.7) 2 (0.7)
2 2 (0.7) 3 (1.1)
3 26 (9.3) 13 (4.7)
4 16 (5.7) 4 (1.4)
5 21 (7.5) 4 (1.4)
6 6 (2.1) 12 (4.3)
7 208 (74.0) 238 (86.2)
NOTE. Values are n (%) or as otherwise indicated.
CVC, central venous catheter; IV, intravenous; NA, not applicable; PICC, peripherally inserted central catheter.
*Mann-Whitney U test.
†Fisher’ exact test.
‡Results are given for 205 devices (60 CVCs) in the neutral-displacement group and 222 devices (64 CVCs) in the positive-displacement group. For the remaining CVCs-
devices, the date of CVC insertion was not available because the CVCs were inserted in another hospital and the date was not documented in our hospital records.
§Kendall τ-b.
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device group. Most microorganisms isolated were skin or environ-
mental bacteria.
Discussion
In a previous laboratory study, the positive-displacement device
used during the study was associated with lower rates of micro-
bial ingress.7 These results were supported by the current study,
whereby the rate of internal ﬂuid pathway contamination was lower
in the positive-displacement group despite being in situ for longer.
These lower contamination rates may be related to the topogra-
phy of the septa, which inﬂuences decontamination eﬃcacy. This
is supported by microbial contamination of the septa also being
lower in this group.
The rate of CLABSI and non–MBI-LCBI CLABSI did not increase
after implementation of the positive-displacement device nor did
it decrease after its withdrawal. Indeed, this device was not used
in any of the hospitals which previously reported an increase in BSI.1
Furthermore, a recent meta-analysis demonstrated that this device
was associated with a lower risk of CLABSI compared with other
devices.8
It has been suggested that the infection risk associated with
needleless IV access devices may be reduced according to 9
criteria.9 Interestingly, the positive-displacement device in this
study fulﬁlled most of the criteria, including transparency, simple
internal design, ease of decontamination, and a tight septum
seal.
This study is not without limitations; indeed Perez et al sug-
gested somemicroorganisms from the internal surfaces of needleless
connectors are nonculturable.10 However, ﬁndings from this study
and previous publications on this positive-displacement device
suggest that the infection risk associated with needleless IV access
device is device speciﬁc and not class speciﬁc.
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Table 2
Rate and extent of microbial contamination in a neutral- and positive-displacement needleless IV access device after up to 7 days of clinical use
Parameters determined Neutral-displacement device Positive-displacement device OR (95% CI) P value
No. of devices cultured 281 276
No. of devices with contaminated septum 118 (42) 79 (29) 1.81 (1.27-2.57) .001*
Median/mean number of CFU isolated from septum (ﬁrst, third
quartile)/(range)
7.5/16.95
(3, 20.75)/(1-121)
7.0/18.82
(4, 16)/(1-197)
.67†‡
No. of patients with ≥1 device with contaminated septum 61 (73) 42 (54) 2.27 (1.18-4.37) .015*
No. of devices with contaminated internal ﬂuid path 37 (13) 11 (4) 3.65 (1.82-7.32) .0001*
Median/mean number of CFU isolated from internal ﬂuid path
(ﬁrst, third quartile)/(range)§
0.5/7.74
(0.5, 3.5)/(0.5-83)
0.5/6.45
(0.5, 11.75)/(0.5-22.5)
.77†¶
No. of patients with ≥1 device with contaminated internal ﬂuid path 31 (37) 6 (8) 7.02 (2.73-18.03) <.0001*
NOTE. Values are n (%) or as otherwise indicated.
CFU, colony forming units; CI, conﬁdence interval; IV, intravenous; OR, odds ratio.
*Fisher’s exact test.
†Mann-Whitney U test: median, mean, quartile, and range values represent positive cultures only.
‡Neutral-displacement devices: n = 118, and positive-displacement devices: n = 79.
§Minimum detection level of 2 CFU per device.
¶Neutral-displacement devices: n = 37, and positive-displacement devices: n = 11.
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